<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02697071</url>
  </required_header>
  <id_info>
    <org_study_id>1921</org_study_id>
    <nct_id>NCT02697071</nct_id>
  </id_info>
  <brief_title>Ketamine for Acute Migraine in the Emergency Department</brief_title>
  <official_title>A Randomized Placebo-Controlled Trial of Sub-Dissociative Ketamine for Treatment of Acute Migraine-Type Headache in the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carilion Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Virginia Polytechnic Institute and State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Carilion Clinic</source>
  <brief_summary>
    <textblock>
      This research study will be a prospective, randomized, double-blind, placebo-controlled&#xD;
      trial. Because ketamine has yet to be directly studied as treatment for acute migraine&#xD;
      headache in the emergency department, the research team is initially interested if ketamine&#xD;
      can reduce pain scores in headache patients and reduce the incidence of recurrence while&#xD;
      exhibiting an adequate safety profile. By using a placebo-controlled study design, the&#xD;
      research team can adequately investigate the effectiveness of the medication in a subgroup&#xD;
      previously not well studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose enrollment of patients upon or shortly after presentation to the&#xD;
      emergency department for treatment with ketamine or placebo. 30 minutes after study drug is&#xD;
      administered, patients will have the option to request rescue medication which will be&#xD;
      ordered by the treating physician according to standard emergency department protocol. Pain&#xD;
      scores will be documented using the Numerical rating scale (NRS-11), 4-Point Pain Intensity&#xD;
      Categorical Scale, and 4-Point Functional Disability Scale at 0 minutes, 30 minutes, and 60&#xD;
      minutes post treatment. Follow-up telephone calls will be made 72-120 hours after treatment&#xD;
      to assess the incidence of recurrence of head pain and patient satisfaction with the&#xD;
      treatment.&#xD;
&#xD;
      Subjects eligible for this study must present to the emergency department with a chief&#xD;
      complaint of primary headache that is determined non-emergent by the treating physician.&#xD;
&#xD;
      Upon block randomization, each subject will receive an intravenous dose of 0.2 mg/kg, with a&#xD;
      maximum dose of 30mg, of ketamine or an equivalent volume of saline. After 30 minutes&#xD;
      patients will be asked if they need rescue medication, and the treating physician will&#xD;
      administer rescue treatment, if requested.&#xD;
&#xD;
      The research hypotheses include:&#xD;
&#xD;
        1. The proportion of patients achieving significant pain reduction at 30 minutes will be&#xD;
           higher in the ketamine treatment group compared to the placebo group.&#xD;
&#xD;
        2. The proportion of patients experiencing pain response, defined as &lt;50% reduction in the&#xD;
           visual analog score compare to the baseline and a reduction of the 4-Point Pain&#xD;
           Intensity Categorical Scale to a 1 or 0, will be higher for patients receiving ketamine&#xD;
           compared to those receiving the placebo.&#xD;
&#xD;
        3. Patients treated with ketamine for headache will experience lower recurrence rates&#xD;
           within 24 hours&#xD;
&#xD;
        4. Ketamine will demonstrate an adequate safety profile.&#xD;
&#xD;
      The last two questions will be exploratory and not included in the power analysis.&#xD;
&#xD;
      It is expected that ketamine will demonstrate a satisfactory safety profile with limited side&#xD;
      effects. The proportion of patients attaining pain response is expected to be higher in the&#xD;
      ketamine treatment group compared to placebo. It is also expected that patients treated with&#xD;
      ketamine alone will be less likely to experience a recurring headache within 72 hours of&#xD;
      treatment than those treated with placebo and rescue medication.&#xD;
&#xD;
      The primary outcome will be achievement of pain response at 30 minutes after ketamine dose.&#xD;
      Achievement of pain response will be defined as reduction in baseline pain score by at least&#xD;
      50% on the NRS scale. Secondary outcomes will include attainment of pain-free state, patient&#xD;
      headache relief, recurrence of headache, recovery of functional disability, and need for&#xD;
      rescue medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of Pain Response After Ketamine Dose.</measure>
    <time_frame>30 minutes</time_frame>
    <description>NRS (National rating scale) pain score change from baseline following ketamine dose. Minimum score is 0, maximum score is 10, and higher scores mean worse pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Categorical Pain Score Change From Baseline</measure>
    <time_frame>30 minutes</time_frame>
    <description>change in baseline categorical pain score at 30 minutes (categorical pain intensity score from 0 to 3 where 0=&quot;no headache&quot; and 3=&quot;severe headache&quot;)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Functional Disability Score Change From Baseline</measure>
    <time_frame>30 minutes</time_frame>
    <description>change in functional disability from baseline at 30 minutes (functional disability score from 0 to 3 where 0=&quot;no disruption of daily activities&quot; and 3=&quot;performance of daily activities is severely impaired&quot;)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Headache</condition>
  <arm_group>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive an equivalent volume of normal saline intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 0.2mg/kg ketamine intravenously over one minute.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Patients in this arm will receive 0.2mg/kg ketamine intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Patients will receive normal saline intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.</description>
    <arm_group_label>Placebo Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-65 years of age&#xD;
&#xD;
          -  Chief complaint of headache&#xD;
&#xD;
          -  International Classification of Headache Disorder classification of migraine or&#xD;
             probable migraine with or without aura&#xD;
&#xD;
          -  Has decision making capacity&#xD;
&#xD;
          -  Consent&#xD;
&#xD;
          -  Provider determination of non-emergent cause&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Over the age of 50 with first time headache&#xD;
&#xD;
          -  Known adverse reaction or tolerance to study medication&#xD;
&#xD;
          -  Headache due to trauma&#xD;
&#xD;
          -  New onset, focal, abnormal, neurologic findings&#xD;
&#xD;
          -  New onset seizures&#xD;
&#xD;
          -  History of metastatic cancer or neoplasm&#xD;
&#xD;
          -  Active psychotic symptoms&#xD;
&#xD;
          -  Altered mental status&#xD;
&#xD;
          -  Provider intends to preform lumbar puncture&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Previous enrollment in study&#xD;
&#xD;
          -  Fever &gt; 100.3 F&#xD;
&#xD;
          -  Physiologic instability (blood pressure &lt; 90/50 or &gt;170/100, heart rate &lt;50 or &gt;120,&#xD;
             chronic respiratory, renal or hepatic failure)&#xD;
&#xD;
          -  Suspected cardiac pain&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corey Corey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carilion Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carilion Roanoke Memorial Emergency Department</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 24, 2016</study_first_submitted>
  <study_first_submitted_qc>February 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2016</study_first_posted>
  <results_first_submitted>November 5, 2020</results_first_submitted>
  <results_first_submitted_qc>February 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 25, 2021</results_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Carilion Clinic</investigator_affiliation>
    <investigator_full_name>Corey Heitz</investigator_full_name>
    <investigator_title>Director of Undergraduate Medical Education, Department of Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Migraine</keyword>
  <keyword>Headache</keyword>
  <keyword>Emergency Department</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT02697071/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Control</title>
          <description>Patients will receive an equivalent volume of normal saline intravenously.&#xD;
Normal Saline: Patients will receive normal saline intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.</description>
        </group>
        <group group_id="P2">
          <title>Ketamine</title>
          <description>Patients will receive 0.2mg/kg ketamine intravenously over one minute.&#xD;
Ketamine: Patients in this arm will receive 0.2mg/kg ketamine intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Control</title>
          <description>Patients will receive an equivalent volume of normal saline intravenously.&#xD;
Normal Saline: Patients will receive normal saline intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.</description>
        </group>
        <group group_id="B2">
          <title>Ketamine</title>
          <description>Patients will receive 0.2mg/kg ketamine intravenously over one minute.&#xD;
Ketamine: Patients in this arm will receive 0.2mg/kg ketamine intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.5" spread="8.3"/>
                    <measurement group_id="B2" value="38.5" spread="13.75"/>
                    <measurement group_id="B3" value="34.3" spread="11.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Headache duration</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Days (&gt;24h)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hours (&lt;24h)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Weeks (&gt;7d)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Self-medicated before ED presentation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual Aura Present</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Classification of Headache Disorders</title>
          <description>Participants were categorized using the International Classification of Headache Disorders (ICD-3) into groups based on migraine without (1.1) or with aura (1.2), or probably migraine without (1.5.1) or with (1.5.2) aura. https://ichd-3.org/1-migraine/</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>1.1 - Migraine without aura</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.2 - Migraine with aura</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5.1 - Probably migraine without aura</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5.2 - probably migraine with aura</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline categorical pain intensity</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe-moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline functional disability</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No disruption</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mildly impaired</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderately impaired</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severely impaired</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline NRS</title>
          <description>NRS = numerical rating scale for pain, from 0-10, where 0 is no pain, and 10 is the most pain they have felt/can imagine feeling. 1-3 are &quot;mild&quot;, 4-6 are &quot;moderate&quot;, and 7-10 are considered &quot;severe&quot; pain.</description>
          <units>scores on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" lower_limit="7" upper_limit="9"/>
                    <measurement group_id="B2" value="8.25" lower_limit="7.75" upper_limit="10"/>
                    <measurement group_id="B3" value="8" lower_limit="7" upper_limit="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Achievement of Pain Response After Ketamine Dose.</title>
        <description>NRS (National rating scale) pain score change from baseline following ketamine dose. Minimum score is 0, maximum score is 10, and higher scores mean worse pain.</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Control</title>
            <description>Patients will receive an equivalent volume of normal saline intravenously.&#xD;
Normal Saline: Patients will receive normal saline intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.</description>
          </group>
          <group group_id="O2">
            <title>Ketamine</title>
            <description>Patients will receive 0.2mg/kg ketamine intravenously over one minute.&#xD;
Ketamine: Patients in this arm will receive 0.2mg/kg ketamine intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement of Pain Response After Ketamine Dose.</title>
          <description>NRS (National rating scale) pain score change from baseline following ketamine dose. Minimum score is 0, maximum score is 10, and higher scores mean worse pain.</description>
          <units>change in score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0" upper_limit="3.75"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0" upper_limit="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Categorical Pain Score Change From Baseline</title>
        <description>change in baseline categorical pain score at 30 minutes (categorical pain intensity score from 0 to 3 where 0=&quot;no headache&quot; and 3=&quot;severe headache&quot;)</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Control</title>
            <description>Patients will receive an equivalent volume of normal saline intravenously.&#xD;
Normal Saline: Patients will receive normal saline intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.</description>
          </group>
          <group group_id="O2">
            <title>Ketamine</title>
            <description>Patients will receive 0.2mg/kg ketamine intravenously over one minute.&#xD;
Ketamine: Patients in this arm will receive 0.2mg/kg ketamine intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Categorical Pain Score Change From Baseline</title>
          <description>change in baseline categorical pain score at 30 minutes (categorical pain intensity score from 0 to 3 where 0=&quot;no headache&quot; and 3=&quot;severe headache&quot;)</description>
          <units>change in score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" lower_limit="0.61" upper_limit="0.83"/>
                    <measurement group_id="O2" value="0.56" lower_limit="0.44" upper_limit="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Functional Disability Score Change From Baseline</title>
        <description>change in functional disability from baseline at 30 minutes (functional disability score from 0 to 3 where 0=&quot;no disruption of daily activities&quot; and 3=&quot;performance of daily activities is severely impaired&quot;)</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Control</title>
            <description>Patients will receive an equivalent volume of normal saline intravenously.&#xD;
Normal Saline: Patients will receive normal saline intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.</description>
          </group>
          <group group_id="O2">
            <title>Ketamine</title>
            <description>Patients will receive 0.2mg/kg ketamine intravenously over one minute.&#xD;
Ketamine: Patients in this arm will receive 0.2mg/kg ketamine intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Disability Score Change From Baseline</title>
          <description>change in functional disability from baseline at 30 minutes (functional disability score from 0 to 3 where 0=&quot;no disruption of daily activities&quot; and 3=&quot;performance of daily activities is severely impaired&quot;)</description>
          <units>change in score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" lower_limit="0.3" upper_limit="0.48"/>
                    <measurement group_id="O2" value="0.44" lower_limit="0.32" upper_limit="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Control</title>
          <description>Patients will receive an equivalent volume of normal saline intravenously.&#xD;
Normal Saline: Patients will receive normal saline intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.</description>
        </group>
        <group group_id="E2">
          <title>Ketamine</title>
          <description>Patients will receive 0.2mg/kg ketamine intravenously over one minute.&#xD;
Ketamine: Patients in this arm will receive 0.2mg/kg ketamine intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A limitation in our study was the chosen ketamine dose. The subjective quality of patient-reported data in pain studies is a limitation.&#xD;
Another limitation in our study was maintaining strict control over additional medications given before or within 30 minutes of study drug administration.&#xD;
Another limitation was quantification of worsening migraine side effects. The final limitations include study location and sample size - single institution in a small city surrounded by a rural area.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Corey Heitz, MD</name_or_title>
      <organization>Lewis Gale Medical Center</organization>
      <phone>5406322364</phone>
      <email>coreyheitzmd@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

